Alimera's European application for expanded use of Iluvien under review

|About: Alimera Sciences, Inc. (ALIM)|By:, SA News Editor

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) accepts for review Alimera Sciences (ALIM +0.8%) marketing application seeking approval to use ILUVIEN (fluocinolone acetonide intravitreal implant) to treat recurrent/persistent non-infectious uveitis affecting the posterior segment.

The UK is the Reference Member State so approval there will apply throughout the EU.

ILUVIEN is currently approved in Europe to treat vision impairment associated with chronic diabetic macular edema.